Nagendran Sukumar (CIK 1665124) reported 16 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-04-13). Recent activity: Sell TSHA (200,000 shares), Buy TSHA (19,021 shares), Sell TSHA (89,132 shares), Sell TSHA (26,918 shares), Buy TSHA (111,324 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-13 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 200,000 | $892,000 |
| 2026-04-13 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 19,021 | $32,526 |
| 2026-01-27 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 89,132 | $423,377 |
| 2026-01-27 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 26,918 | $124,092 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 111,324 | $77,927 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 88,676 | $151,636 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 200,000 | $942,000 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 427,000 | $0 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 260,047 | $1.2M |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 70,172 | $49,120 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 39,953 | $68,320 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 110,125 | $523,094 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 260,047 | $444,680 |
| 2025-09-12 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Buy | 41,150 | $28,805 |
| 2025-09-12 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 200,000 | $646,000 |
| 2025-08-22 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | Sell | 57,054 | $162,604 |
Source: SEC Form 4 filings · as of 2026-04-13